{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:04:16Z","timestamp":1771373056327,"version":"3.50.1"},"reference-count":23,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T00:00:00Z","timestamp":1557964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Thoracic Cancer"],"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Afatinib is an irreversible ErbB family blocker that improves progression\u2010free survival (PFS) of advanced <jats:italic>EGFR<\/jats:italic>\u2010mutant lung adenocarcinoma compared to chemotherapy. However, afatinib leads to more adverse events than first\u2010generation EGFR inhibitors. Hence, exploration of the optimal afatinib initial dose and its efficacy and safety in Asian patients has drawn extensive attention.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrospectively evaluated demographic and clinical information, survival data, and adverse events in advanced non\u2010small cell lung cancer patients treated with afatinib from 27 February 2017 to 30 October 2018.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 60 patients were included in the study. Thirty\u2010nine (65%) patients received afatinib as first\u2010line treatment. The median PFS was 12.3 months (95% confidence internal 7.6\u201317.0). Multivariate Cox regression analysis revealed that age, gender, smoking history, baseline brain metastasis status, afatinib starting dose, and mutation type did not significantly influence PFS. No significant difference in median PFS between patients treated with an initial dose of afatinib of 40\u2009mg or 30\u2009mg, either in the first\u2010line (14.5 vs. 5.2\u2009months; <jats:italic>P<\/jats:italic> = 0.101) or in a second or later\u2010line setting (3.0 vs. 5.0\u2009months; <jats:italic>P<\/jats:italic> = 0.375) was observed. The incidence of all grades of rash\/acne (92.5% vs. 61.1%; <jats:italic>P<\/jats:italic> = 0.011) and paronychia (82.5% vs. 50.0%; <jats:italic>P<\/jats:italic> = 0.010) in the 40\u2009mg group was significantly higher than in the 30\u2009mg group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>First\u2010line afatinib treatment is beneficial for advanced lung adenocarcinoma patients with sensitive <jats:italic>EGFR<\/jats:italic> mutations. Initial dose and baseline brain metastasis status do not significantly impact PFS.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1759-7714.13095","type":"journal-article","created":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T17:43:31Z","timestamp":1558028611000},"page":"1461-1468","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive <i>EGFR<\/i> mutations"],"prefix":"10.1111","volume":"10","author":[{"given":"Shouzheng","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Puyuan","family":"Xing","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Cancer Hospital of HuanXing  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuezhi","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7051-7393","authenticated-orcid":false,"given":"Di","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8465-6933","authenticated-orcid":false,"given":"Yuxin","family":"Mu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7361-325X","authenticated-orcid":false,"given":"Junling","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,5,16]]},"reference":[{"key":"e_1_2_6_2_1","unstructured":"NooneAM HowladerN KrapchoM.SEER Cancer Statistics Review 1975\u20132015 based on November 2017 SEER data submission. Bethesda MD: National Cancer Institute;2018. Available from URL:https:\/\/seer.cancer.gov\/csr\/1975_2015\/. Accessed date: May 9 2019."},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000033"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-013-9715-0"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810699"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70393-X"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.2806"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2088"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3007205"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12996"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000504"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.12.014"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00026-1"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.112.197756"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2008.109"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70604-1"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30033-X"},{"key":"e_1_2_6_18_1","first-page":"Cd010383","article-title":"First\u2010line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non\u2010squamous non\u2010small cell lung cancer","author":"Greenhalgh J","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71173-8"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2018.117"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-017-0190-1"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19563"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2015.11.014"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-5110-2"}],"container-title":["Thoracic Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1759-7714.13095","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1759-7714.13095","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1759-7714.13095","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T08:16:47Z","timestamp":1694333807000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1759-7714.13095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,16]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["10.1111\/1759-7714.13095"],"URL":"https:\/\/doi.org\/10.1111\/1759-7714.13095","archive":["Portico"],"relation":{},"ISSN":["1759-7706","1759-7714"],"issn-type":[{"value":"1759-7706","type":"print"},{"value":"1759-7714","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,16]]},"assertion":[{"value":"2019-02-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}